In 1995, practice guidelines recommended a limit of 48 hours after the onset of atrial fibrillation (AF) for cardioversion without anticoagulation. [1] [2] [3] Whether the risk of thromboembolic complications is increased when cardioversion without anticoagulation is performed in less than 48 hours is unknown.
Methods | In the retrospective Finnish CardioVersion study, 4 all patients with a primary diagnosis of AF, aged 18 years or older, with successful cardioversion in the emergency department within the first 48 hours of AF, and residence in the catchment areas of Turku and Kuopio university hospitals from 2003 to 2010 and Pori central hospital during 2010 were included. Clinical details and the occurrence of thromboembolic complications within 30 days after cardioversion were retrospectively collected from medical reports. The primary outcome, a thromboembolic event, was defined as a clinical stroke or systemic embolism confirmed by computerized tomography or magnetic resonance imaging, surgery, or autopsy. Time to cardioversion was determined as the difference between the beginning of arrhythmic symptoms to the exact time of cardioversion. If the duration of arrhythmia was uncertain, the cardioversion Clinical features (age, female sex, heart failure, and diabetes) with independent predictive value for thromboembolic complications were used as covariates in the multivariate analysis based on our previous work. 4 Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc). Twosided differences at P < .05 were considered significant.
Results | Of 2481 patients with acute AF, 5116 successful cardioversions were performed without anticoagulation. The mean age was 61.0 (SD, 12.4) years, 1638 were female (32.0%), and 2434 had more than 1 risk factor for stroke (47.6%). Thirtyeight thromboembolic events occurred in 38 patients (0.7%; 95% CI, 0.5%-1.0%); 31 were strokes. The incidence of thromboembolic complications increased from 0.3% in group 1 to 1.1% in group 3 (P = .004, Table 1 ).
The incidence of thromboembolic complications according to the time to cardioversion in subgroups is presented in Table 1 . In multivariable logistic regression analysis (Table 2) , time to cardioversion longer than 12 hours was an independent predictor for thromboembolic complications (odds ratio of 4.0 [95% CI, 1.7-9.1] between groups 2 and 1 [P = .001]; odds ratio of 3.3 [95% CI, 1.3-8.9] between groups 3 and 1 [P = .02]).
Discussion | Stroke is the most serious complication of AF. After the recommended 3 weeks of therapeutic anticoagulation, the stroke risk in elective cardioversion of AF ranges from 0.3% to 0.8%.
1 In our study, the risk of thromboembolic complications was 0.7% when cardioversion was performed without anticoagulation within 48 hours of AF onset. However, we found that a delay to cardioversion of 12 hours or longer from symptom onset was associated with a greater risk of thromboembolic complications (1.1%). When the duration of AF was less than 12 hours, the risk of thromboembolism was low (0.3%) without anticoagulation. The main limitation of this retrospective study lies on the verification of AF duration based on real-life evaluation in the emergency department.
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Letters

Risk and Benefits of Screening Mammography
To the Editor One of the major conclusions of the recent article by Drs Pace and Keating 1 was that "The net benefit of screening depends greatly on baseline breast cancer risk, which should be incorporated into screening decisions." This seems logical, but I do not believe there is evidence that it is true. The primary reason screening mammography is so controversial is because the most important outcome is mortality, and only 8 old randomized trials have used mortality as an outcome. Recent trials testing new modalities such as ultrasound or magnetic resonance imaging in high-risk groups have used rate of breast cancer detection as an outcome.
2,3 These trials cannot distinguish between detection of potentially lethal cancers and overdiagnosis of indolent, harmless cancers. It seems clear that screening women at high risk results in a higher rate of cancer detection, but breast cancer biology is complex, and it cannot be assumed that the mortality benefit would be proportional. For example, patients with BRCA1 mutations have a high risk of triple-negative cancers, which are not amenable to early detection with mammography and are frequently found as interval cancers. 4 This group might not benefit proportionally. Alternatively, the Gail model is heavily weighted toward predicting risk of hormonally driven tumors. Screening these women might detect a large number of small, indolent luminal A cancers that would increase the rate of overdiagnosis but not necessarily reduce mortality. There are no data to estimate the degree of benefit that any high-risk group may derive from mammography. Women at high risk may have other options for prevention. One of the greatest harms of mammography, one not mentioned in the article, 1 is that it may encourage overreliance for protection on a technique that may or may not be effective. 
Donald R. Lannin, MD
